Lupin is increasing its focus on complex generics, specialty medicines and differentiated products as global patent expiries create opportunities in regulated markets. The company reported growth in the US business during Q4 and FY26, alongside margin expansion and higher profitability. With investments in R&D, a pipeline of first-to-file opportunities and expansion across emerging markets, Lupin is building its presence in respiratory therapies, specialty medicines and higher-value pharmaceutical segments globally.
Business Today, Business News, Lupin FY26 Results, Lupin Q4 Earnings, Ramesh Swaminathan#Lupin #Bets #Complex #Generics #Specialty #Portfolio #Future #Growth1778228334
Bets
business news
business today
complex
Future
Generics
growth
Lupin
Lupin FY26 Results
Lupin Q4 Earnings
portfolio
Ramesh Swaminathan
Specialty
